Annual CFI
-$200.41 M
-$26.43 M-15.19%
31 December 2023
Summary:
Crinetics Pharmaceuticals annual cash flow from investing activities is currently -$200.41 million, with the most recent change of -$26.43 million (-15.19%) on 31 December 2023. During the last 3 years, it has fallen by -$200.63 million (-92456.22%). CRNX annual CFI is now -580.99% below its all-time high of $41.67 million, reached on 31 December 2019.CRNX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$20.60 M
+$74.24 M+138.41%
30 September 2024
Summary:
Crinetics Pharmaceuticals quarterly cash flow from investing activities is currently $20.60 million, with the most recent change of +$74.24 million (+138.41%) on 30 September 2024. Over the past year, it has increased by +$213.90 million (+110.66%). CRNX quarterly CFI is now -57.74% below its all-time high of $48.76 million, reached on 31 March 2023.CRNX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$120.04 M
+$213.90 M+64.05%
30 September 2024
Summary:
Crinetics Pharmaceuticals TTM cash flow from investing activities is currently -$120.04 million, with the most recent change of +$213.90 million (+64.05%) on 30 September 2024. Over the past year, it has dropped by -$43.78 million (-57.42%). CRNX TTM CFI is now -196.91% below its all-time high of $123.87 million, reached on 30 June 2023.CRNX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CRNX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -15.2% | +110.7% | -57.4% |
| 3 y3 years | -10000.0% | +393.3% | -429.6% |
| 5 y5 years | -67.8% | +0.8% | -87.0% |
CRNX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | <-9999.0% | at low | -57.7% | +110.7% | -196.9% | +64.0% |
| 5 y | 5 years | -581.0% | at low | -57.7% | +110.7% | -196.9% | +64.0% |
| alltime | all time | -581.0% | at low | -57.7% | +110.7% | -196.9% | +64.0% |
Crinetics Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $20.60 M(-138.4%) | -$120.04 M(-64.1%) |
| June 2024 | - | -$53.64 M(<-9900.0%) | -$333.94 M(+34.2%) |
| Mar 2024 | - | $309.00 K(-100.4%) | -$248.86 M(+24.2%) |
| Dec 2023 | -$200.41 M(+15.2%) | -$87.31 M(-54.8%) | -$200.41 M(+162.8%) |
| Sept 2023 | - | -$193.30 M(-714.9%) | -$76.25 M(-161.6%) |
| June 2023 | - | $31.44 M(-35.5%) | $123.87 M(-251.3%) |
| Mar 2023 | - | $48.76 M(+32.3%) | -$81.84 M(-53.0%) |
| Dec 2022 | -$173.98 M(+208.0%) | $36.85 M(+440.2%) | -$173.98 M(-44.3%) |
| Sept 2022 | - | $6.82 M(-103.9%) | -$312.63 M(-4.2%) |
| June 2022 | - | -$174.27 M(+301.7%) | -$326.48 M(+146.6%) |
| Mar 2022 | - | -$43.38 M(-57.4%) | -$132.37 M(+134.4%) |
| Dec 2021 | -$56.48 M(<-9900.0%) | -$101.80 M(+1349.1%) | -$56.48 M(-255.1%) |
| Sept 2021 | - | -$7.03 M(-135.4%) | $36.42 M(+95.7%) |
| June 2021 | - | $19.84 M(-39.0%) | $18.62 M(+13.7%) |
| Mar 2021 | - | $32.50 M(-465.5%) | $16.38 M(+7448.4%) |
| Dec 2020 | $217.00 K | -$8.89 M(-64.2%) | $217.00 K(-105.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2020 | - | -$24.83 M(-241.1%) | -$3.71 M(-108.9%) |
| June 2020 | - | $17.60 M(+7.7%) | $41.57 M(+24.4%) |
| Mar 2020 | - | $16.34 M(-227.4%) | $33.41 M(-19.8%) |
| Dec 2019 | $41.67 M(-134.9%) | -$12.82 M(-162.7%) | $41.67 M(-164.9%) |
| Sept 2019 | - | $20.45 M(+116.5%) | -$64.19 M(-24.4%) |
| June 2019 | - | $9.44 M(-61.6%) | -$84.89 M(-10.5%) |
| Mar 2019 | - | $24.60 M(-120.7%) | -$94.80 M(-20.6%) |
| Dec 2018 | -$119.46 M(>+9900.0%) | -$118.68 M(>+9900.0%) | -$119.46 M(>+9900.0%) |
| Sept 2018 | - | -$251.00 K(-46.5%) | -$1.01 M(+30.1%) |
| June 2018 | - | -$469.00 K(+722.8%) | -$775.00 K(+127.3%) |
| Mar 2018 | - | -$57.00 K(-75.3%) | -$341.00 K(+12.2%) |
| Dec 2017 | -$304.00 K(+60.0%) | -$231.00 K(+1183.3%) | -$304.00 K(+316.4%) |
| Sept 2017 | - | -$18.00 K(-48.6%) | -$73.00 K(+32.7%) |
| June 2017 | - | -$35.00 K(+75.0%) | -$55.00 K(+175.0%) |
| Mar 2017 | - | -$20.00 K | -$20.00 K |
| Dec 2016 | -$190.00 K | - | - |
FAQ
- What is Crinetics Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals annual CFI year-on-year change?
- What is Crinetics Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals quarterly CFI year-on-year change?
- What is Crinetics Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Crinetics Pharmaceuticals?
- What is Crinetics Pharmaceuticals TTM CFI year-on-year change?
What is Crinetics Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of CRNX is -$200.41 M
What is the all time high annual CFI for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high annual cash flow from investing activities is $41.67 M
What is Crinetics Pharmaceuticals annual CFI year-on-year change?
Over the past year, CRNX annual cash flow from investing activities has changed by -$26.43 M (-15.19%)
What is Crinetics Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of CRNX is $20.60 M
What is the all time high quarterly CFI for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high quarterly cash flow from investing activities is $48.76 M
What is Crinetics Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, CRNX quarterly cash flow from investing activities has changed by +$213.90 M (+110.66%)
What is Crinetics Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of CRNX is -$120.04 M
What is the all time high TTM CFI for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals all-time high TTM cash flow from investing activities is $123.87 M
What is Crinetics Pharmaceuticals TTM CFI year-on-year change?
Over the past year, CRNX TTM cash flow from investing activities has changed by -$43.78 M (-57.42%)